Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Explore this paper's citation graph
Summary
It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.
- Type
- article
- Published
- 2011-08-01
- Cited by
- 4,040
- References
- 23
- OpenAlex
- https://openalex.org/W2160982674
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:11704864
Keywords
Medicine, Erlotinib, Internal medicine, Lung cancer, Gemcitabine
References
- Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China
- Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study
- Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
- Management of the Cutaneous Side Effects of Therapeutic Epidermal Growth Factor Receptor Inhibition
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
- Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
- Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
- Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
- Erlotinib in previously treated non-small-cell lung cancer.
- Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
- Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
- Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.
- Cancer Statistics, 2010
- Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406.
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Cited by
- Primary resistance to ATP-competitive mTOR inhibitors for the treatment of solid tumors
- 肺鳞癌驱动基因研究进展
- Have mutation, will travel: utilizing online patient communities and new trial strategies to optimize clinical research in the era of molecularly diverse oncology.
- Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification
- Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
- Systemic cancer therapy: achievements and challenges that lie ahead
- High-throughput screening identifies aclacinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancer.
- EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study.
- Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer
- Clinical characteristics of patients with bronchioloalveolar carcinoma: a retrospective study of 44 cases.
- Personalizing Therapy in Advanced Non–Small Cell Lung Cancer
- Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug.
- Pemetrexed-Carboplatin Adjuvant Chemotherapy With or Without Gefitinib in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Harbouring EGFR Mutations: A Randomized, Phase II Study
- Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer.
- Targeted immunotherapy for non-small cell lung cancer.
- Epidermal growth factor receptor‐tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: A meta‐analysis
- Combination of stereotactic ablative body radiation with targeted therapies.
- Management of EGFR mutated nonsmall cell lung carcinoma patients
- The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011
- Renal toxicity of anticancer agents targeting HER2 and EGFR
Related papers
- Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.
- Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
- Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
- Abstract 1784: Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
- Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
- Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer
- Data from The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
- A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
- Three Cases of Long-Lasting Tumor Control with Erlotinib after Progression with Gefitinib in Advanced Non-Small Cell Lung Cancer